Adma Biologics price target raised to $15 from $10 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Adma Biologics to $15 from $10 and keeps an Overweight rating on the shares. The analyst says it is “not to late” to look at the stock despite the 162% rally halfway into 2024. Adma has a commercial immunoglobulin intravenous portfolio for the treatment of primary humoral immunodeficiency, the analyst tells investors in a research note. The firm believes the company’s “secret sauce” is ASCENIV, which uses source plasma from donors with sufficient levels of naturally occurring Nab titers to RSV and other infectious pathogens. Cantor thinks Adma “is on a very unique growth path relative to the biopharma peers” and pated its model to account for ” increased conviction.”